Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA clears LigaSure vessel sealer for Medtronic's Hugo surgical robot

FDA clears LigaSure vessel sealer for Medtronic's Hugo surgical robot

New Capabilities

Twenty years of LigaSure vessel sealing now reach robotic surgery, sharpening Medtronic's challenge to Intuitive's da Vinci.

2 days ago: FDA clears LigaSure RAS Maryland jaw device for Hugo

Overview

Updated 8 minutes ago

The Food and Drug Administration cleared Medtronic's LigaSure vessel-sealing jaw for use on its Hugo surgical robot on September 16. LigaSure has sealed vessels in 45 million procedures over two decades; this is its first robotic version, cutting and closing vessels up to 7 millimeters in about two seconds each.

The clearance deepens Medtronic's challenge to Intuitive Surgical's dominant da Vinci platform. Hugo is cleared in the US only for urology so far, with general and gynecologic surgery filings pending. An instrument surgeons already trust makes the platform easier to sell as those broader indications arrive.

Why it matters

Robotic vessel sealing is now an option on Hugo, tightening Medtronic's challenge to Intuitive Surgical's hold on soft-tissue surgery.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

45M+
LigaSure procedures performed worldwide
Two decades of use in open and laparoscopic surgery across 65+ countries; now on a robot for the first time.
7 mm
Maximum vessel diameter LigaSure seals
Seals and cuts vessels, thick tissue, and lymphatics in about two seconds with minimal thermal spread.
35+
Countries using Hugo outside the US
More than 50 urology, general, and gynecologic procedure types run on Hugo internationally.
Dec 2025
FDA cleared Hugo for US urology
Hugo remains commercially available in the US only for urologic procedures so far.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Organizations Involved

Medtronic plc
Medtronic plc
Medical technology company
Developer of Hugo RAS; maker of LigaSure vessel sealing

The world's largest standalone medical device company; Hugo is its robotic surgery platform and LigaSure is its vessel-sealing franchise.
Intuitive Surgical
Intuitive Surgical
Medical device company
Incumbent leader in robotic surgery with the da Vinci platform

Maker of the da Vinci robot, the near-monopoly platform in soft-tissue robotic surgery that Hugo is built to challenge.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Clearing authority for medical devices sold in the US

The federal agency that clears medical devices for sale; its rulings decide which procedures and instruments Hugo can carry in the US.

Timeline

July 2025 September 2026

4 events Latest: 2 days ago
Tap a bar to jump to that date

  1. FDA clears LigaSure RAS Maryland jaw device for Hugo

    Latest Regulatory Clearance

    FDA cleared LigaSure for use with Hugo and the Valleylab FT10 energy platform, closing and cutting vessels up to 7 mm in about two seconds.

  2. Medtronic files to expand Hugo into general and gynecologic surgery

    Regulatory Filing

    Medtronic submitted 510(k) filings for Hugo in general surgery and gynecology, plus a filing for the LigaSure RAS Maryland instrument.

  3. FDA clears Hugo for US urologic surgery

    Regulatory Clearance

    Hugo received 510(k) clearance for urologic procedures, its first US indication, and entered commercial use at US medical centers.

  4. LigaSure RAS Maryland debuts on Hugo in Europe

    Product Launch

    Medtronic introduced the first robotically driven LigaSure instrument on Hugo in Europe after receiving a CE Mark in July 2025.

Scenarios

1

FDA clears Hugo for general surgery and gynecology in the US

Likely Resolves by End of 2027

Discussed by: MedTech Dive and Medtronic's own June 2026 announcement, which noted the 510(k) filings were already submitted

Medtronic's June filings asked for general surgery, including hernia repair, and gynecologic surgery indications. The LigaSure clearance builds the instrument line those procedures need. If the FDA grants these indications, Hugo moves from a urology niche into the two highest-volume soft-tissue robotics markets in the US, putting it in direct competition with da Vinci in the procedures where Intuitive earns most of its revenue.

2

LigaSure on Hugo accelerates US placements and procedure volume

Possible Resolves by May 31, 2027

Discussed by: Newsquawk, which noted instrument clearances "show up in procedure volumes and recurring instrument revenue" rather than in daily share moves

Each new Hugo instrument and indication widens the platform's toolkit and strengthens the pitch to hospital purchasing committees. If hospitals respond, Medtronic's earnings calls will show rising Hugo placements and procedure counts. The signal to watch is recurring instrument revenue, the metric that shows whether surgeons are actually using the platform rather than just testing it.

3

Hugo's US expansion stalls behind instrument and training hurdles

Unlikely Resolves by End of 2027

Discussed by: Quomi, which noted hospitals face training, workflow, and total-cost decisions that regulation alone does not settle

Clearance is necessary but not sufficient: surgical teams must be trained, operating budgets must absorb new instrument costs, and real-world results must justify switching from da Vinci, the platform most surgeons already know. If hospitals treat LigaSure-on-Hugo as a marginal addition rather than a reason to switch, Hugo could stay confined to urology while general and gynecologic clearances linger uncommercialized, mirroring earlier entrants that failed to dent Intuitive's installed base.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

July 2000 to present

Intuitive Surgical's da Vinci establishes the market (2000)

The FDA cleared da Vinci for general laparoscopic surgery in July 2000, and Intuitive built a near-monopoly in soft-tissue robotic surgery. Its locked-in instrument ecosystem made recurring revenue as important as system sales.

Then

da Vinci became the default platform for robotic prostatectomy and other soft-tissue procedures.

Now

The instrument-ecosystem model became the template every challenger, including Medtronic, must break.

Why this matters now

Hugo's strategy of pairing trusted instruments with a new robot is a direct attempt to crack the moat da Vinci built in the 2000s.

2015–2021

Verb Surgical winds down (2015–2021)

Johnson & Johnson and Google's Verily backed Verb Surgical to build a lower-cost, data-driven surgical robot. The venture wound down without bringing a commercial system to market.

Then

Johnson & Johnson absorbed the project and shifted its robotics strategy.

Now

The episode showed that deep pockets and strong engineering alone do not displace an incumbent robot.

Why this matters now

Surgeon trust and instrument fit are what make a robot stick. LigaSure on Hugo is Medtronic's bid to supply exactly that trust.

Late 1990s–2000s

LigaSure becomes the open-surgery standard (late 1990s–2000s)

Covidien brought LigaSure to market as a vessel sealer for surgery. It became a fixture in open and laparoscopic operations, replacing suture ligation and clips in many procedures, and Medtronic acquired it with the 2015 Covidien deal.

Then

LigaSure became one of the most used energy instruments in the world.

Now

Surgeons came to trust its predictable sealing in non-robotic cases.

Why this matters now

That accumulated trust is the asset Medtronic now transfers to the robotic arm, hoping surgeons choose Hugo because the instrument feels familiar.

Sources

(9)
+3
PR Newswire Fierce Biotech MedTech Dive The Robotics Media Medtronic Medtronic Newsroom Quomi Newsquawk BioTechGrid